GDC-2394

• Description:

  GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β) . GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation[1][2].

• UNSPSC:

  12352005

• Target:

  Caspase; Interleukin Related; NOD-like Receptor (NLR)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/gdc-2394.html

• Purity:

  99.87

• Solubility:

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=S (C1=C2OC[C@@H] (NC) CN2N=C1) (NC (NC3=C4CCCC4=CC5=C3CCC5) =O) =O

• Molecular Formula:

  C20H25N5O4S

• Molecular Weight:

  431.51

• References & Citations:

  [1]McBride C, et al. Overcoming Preclinical Safety Obstacles to Discover (S) -N- ((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl) carbamoyl) -6- (methylamino) -6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394) : A Potent and Selective NLRP3 Inhibitor. J Med Chem. 2022 Oct 24. |[2]Stafford, et al. Preparation of hexahydroindacenylcarbamoyldihydropyrazolooxazinesulfonamide derivatives and analogs for use as interleukin-1 activity inhibitors: World Intellectual Property Organization, WO2018136890[P]. 2018-07-26.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  2238822-07-4